Last reviewed · How we verify
Cyclopofol
Cyclopofol, marketed by RenJi Hospital, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current marketed status, which provides a competitive edge over pre-market competitors. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Cyclopofol |
|---|---|
| Also known as | Haisco Pharmaceutical Group Co., Ltd |
| Sponsor | RenJi Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study on Pharmacokinetics of Single Injection of Ciprofol in Patients With Moderate to Severe Hypoproteinemia (PHASE4)
- The Application of Different Sedation Protocols in ICU Patients With Severe Pneumonia
- Explore the Clinical Application Value of Ciprofol in Painless Colonoscopy (NA)
- Cyclopofol Versus Propofol for Postoperative Delirium in Elderly Patients Having Orthopedic Surgery (PHASE4)
- A Clinical Study to Evaluate Cyclopofol Injection for the Prevention of Postoperative Nausea and Vomiting (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |